metformin and glucagon-like peptide 2

metformin has been researched along with glucagon-like peptide 2 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Inoue, T; Kira, K; Nagakura, T; Saeki, T; Tanaka, I; Yamazaki, K; Yasuda, N	1
Aaboe, K; Deacon, CF; Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T	1
Rohde, U	1

Reviews

1 review(s) available for metformin and glucagon-like peptide 2

Article	Year
EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects. Danish medical journal, 2016, Volume: 63, Issue:11 Topics: Animals; Bariatric Surgery; Bile Acids and Salts; Cholecystokinin; Diabetes Mellitus, Type 2; Gastric Bypass; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glycated Hemoglobin; Humans; Incretins; Metformin; Obesity; Weight Loss	2016

Trials

1 trial(s) available for metformin and glucagon-like peptide 2

Article	Year
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:4 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Peptide YY; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles	2010

Article

Year

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.

Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:4

Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Peptide YY; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles

2010

Other Studies

1 other study(ies) available for metformin and glucagon-like peptide 2

Article	Year
The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. European journal of pharmacology, 2004, Mar-19, Volume: 488, Issue:1-3 Topics: Animals; Antimetabolites; Biguanides; Dipeptidyl Peptidase 4; Enteroendocrine Cells; Fluorouracil; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Hypoglycemic Agents; Intestine, Small; Male; Metformin; Mice; Mice, Inbred BALB C; Organ Size; Peptides; Protease Inhibitors; Pyrroles; Rats; Rats, Inbred F344; Valine	2004

Article

Year

The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight.

European journal of pharmacology, 2004, Mar-19, Volume: 488, Issue:1-3

Topics: Animals; Antimetabolites; Biguanides; Dipeptidyl Peptidase 4; Enteroendocrine Cells; Fluorouracil; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Hypoglycemic Agents; Intestine, Small; Male; Metformin; Mice; Mice, Inbred BALB C; Organ Size; Peptides; Protease Inhibitors; Pyrroles; Rats; Rats, Inbred F344; Valine

2004